



Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics.

Everett Clinton Smith, Hervé Blanc, Marco Vignuzzi, Mark R Denison

► To cite this version:

Everett Clinton Smith, Hervé Blanc, Marco Vignuzzi, Mark R Denison. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics.. PLoS Pathogens, 2013, 9 (8), pp.e1003565. 10.1371/journal.ppat.1003565 . pasteur-00918207

HAL Id: pasteur-00918207

<https://pasteur.hal.science/pasteur-00918207>

Submitted on 13 Dec 2013

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics

Everett Clinton Smith^{1,2}, Hervé Blanc³, Marco Vignuzzi³, Mark R. Denison^{1,2,4*}

1 Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, **2** The Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, **3** Institut Pasteur, Centre National de la Recherche Scientifique Unité de Recherche Associée 3015, Paris, France, **4** Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America

Abstract

No therapeutics or vaccines currently exist for human coronaviruses (HCoVs). The Severe Acute Respiratory Syndrome-associated coronavirus (SARS-CoV) epidemic in 2002–2003, and the recent emergence of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in April 2012, emphasize the high probability of future zoonotic HCoV emergence causing severe and lethal human disease. Additionally, the resistance of SARS-CoV to ribavirin (RBV) demonstrates the need to define new targets for inhibition of CoV replication. CoVs express a 3'-to-5' exoribonuclease in nonstructural protein 14 (nsp14-ExoN) that is required for high-fidelity replication and is conserved across the CoV family. All genetic and biochemical data support the hypothesis that nsp14-ExoN has an RNA proofreading function. Thus, we hypothesized that ExoN is responsible for CoV resistance to RNA mutagens. We demonstrate that while wild-type (ExoN+) CoVs were resistant to RBV and 5-fluorouracil (5-FU), CoVs lacking ExoN activity (ExoN-) were up to 300-fold more sensitive. While the primary antiviral activity of RBV against CoVs was not mutagenesis, ExoN- CoVs treated with 5-FU demonstrated both enhanced sensitivity during multi-cycle replication, as well as decreased specific infectivity, consistent with 5-FU functioning as a mutagen. Comparison of full-genome next-generation sequencing of 5-FU treated SARS-CoV populations revealed a 16-fold increase in the number of mutations within the ExoN- population as compared to ExoN+. Ninety percent of these mutations represented A:G and U:C transitions, consistent with 5-FU incorporation during RNA synthesis. Together our results constitute direct evidence that CoV ExoN activity provides a critical proofreading function during virus replication. Furthermore, these studies identify ExoN as the first viral protein distinct from the RdRp that determines the sensitivity of RNA viruses to mutagens. Finally, our results show the importance of ExoN as a target for inhibition, and suggest that small-molecule inhibitors of ExoN activity could be potential pan-CoV therapeutics in combination with RBV or RNA mutagens.

Citation: Smith EC, Blanc H, Vignuzzi M, Denison MR (2013) Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics. *PLoS Pathog* 9(8): e1003565. doi:10.1371/journal.ppat.1003565

Editor: Michael S. Diamond, Washington University School of Medicine, United States of America

Received: May 15, 2013; **Accepted:** July 3, 2013; **Published:** August 15, 2013

Copyright: © 2013 Smith et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was funded by United States National Institutes of Health grants U54-AI057157 (SERCEB; MRD), R01-AI108197 (MRD), T32-AI095202 (ECS) and by the European Union, grants ERC StG no. 242719 and FP7-IRG-2008 no. 239321 (HB, MV). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: mark.denison@Vanderbilt.edu

Introduction

The potential for CoVs to cause significant human disease is well demonstrated, with six known HCoVs—HKU1, OC43, NL63, 229E, SARS-CoV and MERS-CoV—causing colds, pneumonia, systemic infection, and severe or lethal disease [1–5]. Four of these viruses have been identified in just the last 10 years, with two, SARS-CoV and MERS-CoV, causing lethal respiratory and systemic infection [1,3–6]. Studies over the past 10 years have expanded the known phylogenetic, geographic, and species diversity of CoVs, and support multiple emergence events of CoVs into humans from bats and other zoonotic pools [7–10]. The most recent evidence for CoV trans-species movement comes from the emergence of the novel MERS-CoV [1,11,12]. From April 2012 to June 2013 MERS-CoV has caused 72 laboratory confirmed cases and up to 50% mortality from severe respiratory and systemic disease in at least 8 countries, with evidence for

human-to-human transmission [13]. MERS-CoV is most closely related to the bat CoVs HKU4 and HKU5 [11], and the recently identified receptor dipeptidyl peptidase 4 (DPP4) is present on both human and bat cells [14], providing a compelling argument that zoonotic CoV infections resulting in severe human disease may be more frequent events than previously thought. Because of the lack of epidemiological data, it remains unknown whether multiple introductions from a zoonotic source or human transmission of a mild or asymptomatic disease is responsible for these continuing cases of sporadic severe infections. However, based on the high mortality rates associated with SARS-CoV and those reported for MERS-CoV [13], this novel virus potentially represents a serious threat to global health for which no vaccines or therapeutics currently exist.

CoVs contain the largest known RNA genomes (27–32 kb) and encode an array of 16 viral replicase proteins, including a 3'-to-5' exoribonuclease (ExoN) domain within nonstructural protein 14

Author Summary

RNA viruses have high mutation rates (10^{-3} to 10^{-5} mutations/nucleotide/round of replication), allowing for rapid viral adaptation in response to selective pressure. While RNA viruses have long been considered unable to correct mistakes during replication, CoVs such as SARS-CoV and the recently emerged MERS-CoV are important exceptions to this paradigm. All CoVs encode an exoribonuclease activity in nonstructural protein 14 (nsp14-ExoN) that is proposed to prevent and/or remove misincorporated nucleotides. Because of the demonstrated resistance of SARS-CoV to the antiviral drug ribavirin (RBV), we hypothesized that ExoN is responsible for CoV resistance to RNA mutagens. Using RBV and the RNA mutagen 5-fluorouracil (5-FU), we show that CoVs lacking ExoN activity (ExoN⁻) are highly susceptible to RBV and 5-FU, in contrast to wild-type (ExoN⁺) CoVs. The inhibitory activity of 5-FU against ExoN⁻ viruses resulted specifically from 5-FU incorporation during viral RNA synthesis that lead to extensive mutagenesis within the viral population, and was associated with a profound decrease in virus specific infectivity. These results demonstrate the proof-reading activity of ExoN during virus replication and suggest that inhibitors of ExoN activity could be broadly useful inhibitors of CoV replication in combination with RBV or RNA mutagens.

(nsp14) [2,15–17]. Similar to the proofreading subunit (ϵ) of *E. coli* DNA polymerase III, CoV nsp14-ExoN is a member of the DEDD superfamily of DNA and RNA exonucleases [15,18]. This superfamily contains four conserved D-E-D-D acidic residues that are required for enzymatic activity, and mutation of these critical residues within CoV ExoN ablates or significantly reduces ExoN activity [15]. Studies from our group have demonstrated that ExoN activity is essential for high-fidelity replication in both the model CoV murine hepatitis virus (MHV) and SARS-CoV [19,20]. Inactivation of ExoN activity due to alanine substitution of the first two active site residues results in 15- to 20-fold reduced replication fidelity in cell culture [19,20] and a 12-fold reduction during SARS-CoV infection *in vivo* [21], associated with profound and stable attenuation of SARS-CoV virulence and replication. A recent study has shown that bacterially-expressed SARS-CoV nsp14-ExoN can remove mismatched nucleotides *in vitro*, and that ExoN activity is stimulated *in vitro* through interactions with the non-enzymatic CoV protein nsp10 [22]. Thus all bioinformatic, genetic and biochemical studies to date support the hypothesis that nsp14-ExoN is the first identified proofreading enzyme for an RNA virus and functions together with other CoV replicase proteins to perform the crucial role of maintaining CoV replication fidelity.

Retrospective clinical studies during the SARS epidemic ultimately concluded that treatment with ribavirin (RBV), an antiviral drug shown to be mutagenic for some RNA viruses [23,24], was ineffective against SARS-CoV [25–28]. Because ExoN activity is required for CoV high-fidelity replication [19–21], we sought to determine if ExoN was responsible for CoV resistance to RNA mutagens. Using the nucleoside analog RBV and the base analog 5-fluorouracil (5-FU; [29]) we show that CoVs lacking ExoN activity (ExoN⁻) are up to 300-fold more sensitive to inhibition than wild-type CoVs (ExoN⁺). Additionally, using full-genome next-generation sequencing we show that ExoN⁻ viruses accumulate 15- to 20-fold more A:G and U:C transitions, consistent with 5-FU incorporation during RNA synthesis. Ultimately our results suggest the exciting possibility that small-molecule inhibitors of ExoN

activity could be potential pan-CoV therapeutics, especially when used in combination with RBV or RNA mutagens.

Materials and Methods

Cell culture and viruses

Murine astrocytoma delayed brain tumor cells (DBT cells) were grown at 37°C and maintained in DMEM (Invitrogen) containing 10% FBS, supplemented with penicillin, streptomycin, HEPES, and amphotericin B. VeroE6 (Vero) cells were grown at 37°C and maintained in MEM (Invitrogen) containing 10% FBS supplemented with penicillin, streptomycin, and amphotericin B. All work with MHV was performed using the reverse genetics infectious clone based on strain MHV-A59 [30], and work with SARS-CoV was performed using the reverse genetics infectious clone based on the Urbani strain [31]. Viral studies using SARS-CoV were performed in Select Agent certified BSL-3 laboratories using protocols reviewed and approved by the Institutional Biosafety Committee of Vanderbilt University and the Centers for Disease Control for the safe study and maintenance of SARS-CoV.

Compounds and cell viability studies

5-fluorouracil (5-FU), ribavirin (RBV), guanosine (GUA) and mycophenolic acid (MPA) were obtained from Sigma. 5-FU and RBV were made as 200 mM stock solutions, and were prepared in DMSO and sterile water, respectively. GUA and MPA were prepared in DMSO as 40 mM or 100 mM stocks, respectively. Low concentration (μ M) working stocks were prepared as needed in sterile water prior to dilution in DMEM. Viability of DBT and Vero cells was assessed using CellTiter-Glo (Promega) in 96-well plate format according to manufacturer's instructions. DBT and Vero cells were seeded into opaque tissue culture grade 96-well plates, and DMEM containing RBV or 5-FU was added to each well to achieve the concentrations indicated. Water or DMSO vehicle controls were performed, in addition to a 20% ethanol control for cell death. The cells were then incubated at 37°C for either 12 or 24 h, and cell viability was determined using a Veritas Microplate Luminometer (Promega). The resultant values were then normalized to untreated cells.

Drug sensitivity studies and plaque assays

Subconfluent monolayers of DBT cells in 6-well plates were pretreated for 30 min at 37°C with 1 mL of DMEM containing vehicle or the indicated concentration of RBV, 5-FU, MPA, or GUA. The drug was then removed and cells were infected with MHV-ExoN⁺ or ExoN⁻ viruses at an MOI of 1 plaque forming units (PFU)/cell (single-cycle) or 0.01 (multi-cycle) for 30 min at 37°C. Virus was then removed and 1 mL of DMEM containing vehicle, RBV, 5-FU, MPA, or GUA was added to each well. Cells were then incubated at 37°C for either 12 (single-cycle) or 24 (multi-cycle) h. The supernatant was harvested and virus titer was determined by plaque assay on DBT cells. For SARS-CoV studies, subconfluent monolayers of Vero cells in T25 flasks were pretreated for 30 min at 37°C with DMEM containing vehicle, RBV, or 5-FU. The drug was removed and cells were infected with either SARS-ExoN⁺ or ExoN⁻ viruses at an MOI of 0.1 PFU/cell (single-cycle) for 30 min. The virus was removed and DMEM containing vehicle, RBV, or 5-FU was added back. Cells were then incubated for 24 h, at which point the supernatant was harvested and virus titer was determined by plaque assay on Vero cells. All treated samples were normalized to the untreated vehicle control, and values were expressed as fold change from untreated virus titers.

Real-time quantitative reverse transcription PCR (real-time qRT-PCR) of viral genomic RNA

Viral RNA was harvested from infected cell monolayers using TRIzol reagent (Invitrogen), and was reverse transcribed (RT) using SuperScript III (Invitrogen). Random hexamers (1 μ L of 50 μ M stock) and 1 μ g of total RNA were incubated for 5 min at 70°C. The remaining reagents were then added according to the manufacturer's protocol, and the mixture was incubated at 50°C for 1 h and then at 85°C for 5 min. All RT reactions were performed in a final volume of 20 μ L. Real-time qRT-PCR was performed on the RT product using the Applied Biosciences 7500 Real-Time PCR System with Power SYBR Green PCR Master Mix (Life Technologies). Each reaction was performed in a total volume of 25 μ L containing 12.5 μ L of the Power SYBR Green PCR Master Mix, 125 ng each of the forward and reverse primers and 1 μ L of the RT product which was diluted 1:1000. Viral genomic RNA was detected using primers (forward: ACAGGGTGGAGTTCCCGTTA and reverse: ACGGAAG-CACCACCATAAGA) optimized to generate a \sim 120 nt portion of ORF1a. These values were normalized using the $2^{-\Delta\Delta C_t}$ method [32] to endogenous expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using primers (forward: GGGTGTGAACACGAGAAAT and reverse: CCTTCCACAATGCCAAAGTT) optimized to yield a \sim 120 nt portion of GAPDH [33,34]. Triplicate wells of each sample were analyzed, and averaged into one value representing a single replicate to minimize well-to-well variation. The cycle parameters were as follows: Stage 1, (1 rep) at 50°C for 2 min; Stage 2, (1 rep) 95°C for 10 min; Stage 3, (40 reps) at 95°C for 15 sec and 57°C for 1 min. One representative product from each treatment was verified by melting curve analysis and agarose gel electrophoresis.

Amplicon preparation for deep sequencing of whole viral genomes

Viral RNA from SARS-ExoN+ or ExoN– infected Vero monolayers was harvested using TRIzol reagent, and was reverse transcribed (RT) using SuperScript III as described above except with 5 μ L of random hexamers (50 μ M stock), 5 μ g of total RNA, and in a final volume of 100 μ L for each reaction. Four microliters of RT product was then used to generate 12 overlapping \sim 3 kb amplicons for each virus treated with either 0 or 400 μ M 5-FU by PCR. The high-fidelity polymerase Easy A (Agilent) was used to ensure that errors were minimal during PCR. All primer sets generated single bands which were then purified using the Wizard SV Gel and PCR Clean-Up System (Promega).

Illumina next generation sequencing and analysis

Prior to sequencing, cDNA amplicons were fragmented (Fragmentase, NEB), clustered, and sequenced with Illumina cBot and GAIIIX technology as previously described [35]. Between 1.4×10^8 and 4.5×10^8 bases, comprised of \sim 69-nt reads, were obtained per virus, and CASAVA 1.8.2 was used to demultiplex and create the fastq files. Low quality bases from the ends of each sequence read were then trimmed, using *Phred* scores as the guiding metric (error probabilities higher than 0.001), and sequences with less than 16 bases after trimming were discarded to reduce false alignment and subsequent false variant calls. The program fastq-clipper (http://hannonlab.cshl.edu/fastx_toolkit/index.html) was used for this quality filtering. The Burrows-Wheeler Alignment tool was then used to align reads to the SARS-CoV ExoN+ or ExoN– reference genomes with a maximum of two mismatches per read [36]. Base calling at each position was determined using SAMTOOLS [37]. After the pileup, an in-house

script collected the data per-position. For each position throughout the viral genome, the bases and their qualities were gathered, each variant allele's rate was initially modified according to its covering read qualities based on a maximum likelihood estimation and test for significance using Wilks' theorem. Additionally, an allele confidence interval was calculated and output for each allele. Only alleles with statistically significant $p < 0.05$ values were retained and considered to be true variants. Above 0.01% all variants were found to be statistically significant, while below 0.01% many variants could not be distinguished from background error. Thus, the background noise caused by sequencing error was determined to be 0.01% or less.

Statistical analysis

Statistical tests were applied where noted within the figure legends and were determined using GraphPad Prism (La Jolla, CA) software. Statistical significance is denoted (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.0001$) and was determined using an unpaired, two-tailed Student's *t* test compared to either untreated samples or to the corresponding ExoN+ sample. For the cell viability studies, treated samples were compared to the DMEM sample containing DMSO.

Results

MHV-ExoN– viruses have increased sensitivity to RBV

Because RBV has been shown to be incorporated as ribavirin monophosphate (RMP) into viral RNA during replication [23,24,38–42], the presence of a proofreading enzyme would be predicted to exclude and/or remove nucleotide misincorporation [43–47]. If ExoN is responsible for the resistance phenotype, viruses lacking ExoN activity (ExoN–) should demonstrate increased titer reduction following RBV treatment as compared to wild-type viruses containing ExoN activity (ExoN+). To test this hypothesis, we examined the sensitivity of MHV-ExoN+ and ExoN– viruses to RBV during single-cycle (MOI = 1 PFU/cell) replication in murine astrocytoma delayed brain tumor cells (DBT cells). No toxicity was observed in DBT cells following treatment with up to 400 μ M RBV (Figure 1A). MHV-ExoN+ viruses were resistant to 10 μ M RBV (Figure 1B), while MHV-ExoN– virus titers decreased by \sim 200-fold following treatment with 10 μ M RBV. The capacity of 10 μ M RBV to inhibit MHV-ExoN– replication is surprising because at least 10-fold higher concentrations of RBV are required to inhibit poliovirus and chikungunya viruses [48–50]. This observation could be due to the longer genomes of CoVs or to the mechanism(s) by which RBV inhibits CoV replication.

The antiviral activity of RBV against ExoN– viruses is not primarily due to mutagenesis

If RBV is exerting antiviral activity primarily through mutagenesis following incorporation of RMP, MHV-ExoN– viruses should exhibit increased sensitivity during multi-cycle replication. To test this, we determined the sensitivity of MHV-ExoN+ and ExoN– viruses to RBV at a low multiplicity of infection (MOI = 0.01 PFU/cell). Unexpectedly, multi-cycle replication of MHV-ExoN– viruses in the presence of RBV (Figure 1B) was indistinguishable from single-cycle replication.

RBV has been reported to exert antiviral activity through numerous mechanisms [38] including disruption of viral RNA synthesis and inhibition of the cellular enzyme inosine monophosphate dehydrogenase (IMPDH). To determine if RBV treatment was affecting CoV RNA synthesis, we performed two-step real-time quantitative reverse transcription PCR (real-time qRT-PCR)




Figure 1. The antiviral activity of RBV against ExoN⁻ viruses is not primarily due to mutagenesis. (A) DBT cells in 96-well plates were incubated with DMEM alone, or DMEM containing 20% ethanol (EtOH), 4% DMSO, or the indicated concentration of RBV for 12 h. Cell viability was determined using CellTiter-Glo (Promega) according to manufacturer's instructions. All values were normalized to the untreated (DMEM) control. No significant differences were found when RBV-treated values were compared to DMEM samples containing DMSO (+DMSO) using an unpaired, two-tailed Student's *t* test. Mean values \pm S.E.M. are shown, *n* = 2. (B) MHV-ExoN⁺ (filled circle) and MHV-ExoN⁻ (open circle) virus sensitivity to RBV during single- (solid lines; MOI = 1 PFU/cell) and multi-cycle (dotted lines; MOI = 0.01 PFU/cell) replication. MHV-ExoN⁺ viruses are shown in blue and MHV-ExoN⁻ viruses are shown in green. The change in virus titer was calculated by dividing virus titers following treatment by the untreated controls. Mean values \pm S.E.M. are shown, *n* = 4. (C) The change in titer (filled bars) and genomic RNA levels (hatched bars) of MHV-ExoN⁺ (blue) and MHV-ExoN⁻ (green) viruses following treatment with RBV is shown. DBT cells were infected with MHV-ExoN⁺ or MHV-ExoN⁻ in the presence or absence of RBV, and virus titer was determined by plaque assay. Genomic RNA levels were determined using two-step real-time qRT-PCR and primers

optimized to amplify a ~120 nt region of ORF1a [33]. The change in genomic RNA levels ($2^{-\Delta\Delta C_t}$) is shown relative to endogenous GAPDH expression and was normalized to RNA levels from untreated samples. Mean values \pm S.E.M. are shown, $n=6$. (D) MHV-ExoN+ (filled circle) and MHV-ExoN- (open circle) virus sensitivity to mycophenolic acid (MPA) during single- (solid lines; MOI=1 PFU/cell) and multi-cycle (dotted lines; MOI=0.01 PFU/cell) replication. Mean values \pm S.E.M. are shown, $n=2-4$. RBV- or MPA-treated MHV-ExoN+ (E) and MHV-ExoN- (F) viruses with or without the addition of 100 μ M guanosine (GUA) during single-cycle replication (MOI=1 PFU/cell). Mean values \pm S.E.M. are shown, $n=2$. For all parts, statistical significance was determined using an unpaired, two-tailed Student's *t* test (* $P<0.05$, ** $P<0.01$, *** $P<0.0001$). doi:10.1371/journal.ppat.1003565.g001

to determine viral genomic RNA levels in the presence or absence of RBV. Similar to Figure 1B, MHV-ExoN+ titers were unaffected, whereas there was a dose-dependent reduction in MHV-ExoN- titers following RBV treatment (Figure 1C, filled bars). Corresponding dose-dependent reductions in MHV-ExoN- genomic RNA were observed (Figure 1C, hatched bars) following RBV treatment, demonstrating that treatment with 10 μ M RBV decreased MHV-ExoN- RNA synthesis by nearly 100-fold during replication. Because RBV caused decreased RNA synthesis in MHV-ExoN- viruses, we calculated the relative specific infectivities of both viruses at each RBV concentration (Table 1). The relative specific infectivity of MHV-ExoN- viruses was decreased by 6- to 9-fold following treatment with RBV, while MHV-ExoN+ viruses were unaffected.

In addition to decreasing viral RNA synthesis, RBV could be exerting antiviral activity against MHV-ExoN- through competitive inhibition of IMPDH by RMP [51]. To test this possible mechanism, we treated MHV-ExoN+ and MHV-ExoN- viruses with the specific IMPDH inhibitor mycophenolic acid (MPA; [52–54]) during both single- and multi-cycle replication. A concentration-dependent decrease in MHV-ExoN- virus titer was observed following MPA treatment during single-cycle replication (Figure 1D). MHV-ExoN+ titers were reduced by less than 10-fold, consistent with what was observed following RBV treatment (Figure 1B). Similar to RBV, increased sensitivity of MHV-ExoN- viruses to MPA was not observed during multi-cycle replication. If RBV is acting via IMPDH inhibition, addition of extracellular guanosine (GUA) should restore virus titers, as has been demonstrated previously for Dengue virus [55]. Addition of 100 μ M GUA following RBV or MPA pretreatment and viral infection had no effect on MHV-ExoN+ viruses (Figure 1E), but completely restored MHV-ExoN- titer even in the continued presence of 10 μ M RBV or 1 μ M MPA (Figure 1F). These data indicate that the antiviral activity of RBV against MHV-ExoN- viruses is occurring at least in part through decreasing viral RNA synthesis and inhibition of IMPDH. Because our primary goal was to test the role of nsp14-ExoN in the prevention and/or removal of nucleotide misincorporation we did not further investigate how RBV was specifically

inhibiting ExoN- viruses. However, these results do show that the presence of ExoN activity is capable of preventing RBV inhibition of CoV replication.

The increased sensitivity of MHV-ExoN- viruses to 5-FU treatment is consistent with mutagenesis

We next examined the sensitivity of MHV-ExoN+ and ExoN- viruses to the pyrimidine base analog 5-FU, which has been shown to be mutagenic for many RNA viruses [29,56]. Treatment of DBT cells with up to 400 μ M 5-FU did not result in any detectable cellular toxicity (Figure 2A). Following treatment with up to 200 μ M 5-FU (Figure 2B) during single-cycle infections, MHV-ExoN+ titers were inhibited less than 3-fold, while titers of MHV-ExoN- decreased ~900 fold, representing a ~300-fold increase in sensitivity as compared to MHV-ExoN+. During multi-cycle replication, MHV-ExoN+ virus titers were reduced by less than 10-fold following 5-FU treatment, while MHV-ExoN- showed a ~50,000-fold reduction in titer (Figure 2B). Virus was undetectable by plaque assay at 5-FU concentrations above 80 μ M. Analysis of viral RNA synthesis by two-step real-time qRT-PCR demonstrated that MHV-ExoN+ RNA levels were not reduced following 5-FU treatment, while 5-FU treatment resulted in minimal two-to-five fold decreases in MHV-ExoN- RNA (Figure 2C). The specific infectivity of MHV-ExoN- was decreased by 14- and 128-fold following treatment with 100 μ M and 200 μ M 5-FU, respectively (Table 1). These results demonstrate that ExoN activity confers resistance to 5-FU, and support the hypothesis that 5-FU is driving increased genomic mutagenesis in MHV-ExoN- virus populations, leading to lethal mutagenesis and extinction.

SARS-ExoN- viruses are sensitive to 5-FU treatment

To determine whether SARS-CoV viruses lacking ExoN activity (SARS-ExoN-) also were inhibited by RBV and 5-FU, we infected Vero cells with either SARS-ExoN+ or ExoN- viruses in the presence or absence of RBV or 5-FU. Treatment of Vero cells with up to 400 μ M RBV or 5-FU did not decrease cell viability by more than 20% (Figure 3A). Recent reports have

Table 1. Relative specific infectivities of MHV-ExoN+ and ExoN- viruses following treatment with RBV or 5-FU.

Virus	RBV(μ M)	Relative Specific Infectivity	Fold Decrease	5-FU (μ M)	Relative Specific Infectivity	Fold Decrease
MHV-ExoN+	0	1		0	1	
	5	1.2 \pm 0.1	0.84 \pm 0.06	100	0.33 \pm 0.05	3.4 \pm 0.5
	10	1.9 \pm 0.2	0.56 \pm 0.05	200	0.24 \pm 0.03	4.5 \pm 0.4
MHV-ExoN-	0	1		0	1	
	5	0.19 \pm 0.04	6.0 \pm 0.7***	100	0.10 \pm 0.03	13.6 \pm 2.9**
	10	0.26 \pm 0.11	9.1 \pm 3.0*	200	0.012 \pm 0.004	128 \pm 29**

Relative specific infectivity values were calculated using the data shown in Figures 1C and 2C and represent the change in virus titer divided by the change in virus genome for each sample. All values are shown relative to untreated virus. The mean value and standard error for each sample is shown (Student's *t* test, $n=4$, * $P<0.05$, ** $P<0.01$, *** $P<0.0001$).

doi:10.1371/journal.ppat.1003565.t001




Figure 2. The increased sensitivity of MHV-ExoN⁻ viruses to 5-FU is consistent with mutagenesis. (A) DBT cells in 96-well plates were incubated with DMEM alone, or DMEM containing 20% ethanol (EtOH), 4% DMSO, or the indicated concentration of 5-FU for 12 h. Cell viability was determined using CellTiter-Glo (Promega) according to manufacturer's instructions. All values were normalized to the untreated (DMEM) control. Mean values \pm S.E.M. are shown, $n=2$. (B) MHV-ExoN⁺ (filled circle) and MHV-ExoN⁻ (open circle) virus sensitivity to 5-FU during single- (solid lines; MOI=1 PFU/cell) and multi-cycle (dotted lines; MOI=0.01 PFU/cell) replication. MHV-ExoN⁺ viruses are shown in blue and MHV-ExoN⁻ viruses are shown in green. The change in virus titer was calculated by dividing virus titers following treatment by the untreated controls. Mean values \pm S.E.M. are shown, $n=4$. (C) The change in titer (filled bars) and genomic RNA levels (hatched bars) of MHV-ExoN⁺ (blue) and MHV-ExoN⁻ (green) viruses following treatment with 5-FU is shown. DBT cells were infected with MHV-ExoN⁺ or MHV-ExoN⁻ in the presence or absence of 5-FU, and virus

titer was determined by plaque assay. Genomic RNA levels were determined using two-step real-time qRT-PCR and primers optimized to amplify a ~120 nt region of ORF1a [33]. The change in genomic RNA levels ($2^{-\Delta\Delta C_t}$) is shown relative to endogenous GAPDH expression and was normalized to RNA levels from untreated samples. Mean values \pm S.E.M. are shown, $n=6$. For all parts, statistical significance was determined using an unpaired, two-tailed Student's t test (* $P<0.05$, ** $P<0.01$, *** $P<0.0001$).

doi:10.1371/journal.ppat.1003565.g002

described the lack of RBV uptake by Vero cells due to the absence of specific equilibrative nucleoside transporters [57,58]. Additionally, previous studies have shown that RBV failed to inhibit SARS-CoV replication in Vero cells [59]. Consistent with those reports, in our experiments both SARS-ExoN⁺ and ExoN⁻ viruses were unaffected by treatment with up to 400 μ M RBV (Figure 3B). We therefore performed subsequent experiments with 5-FU. SARS-ExoN⁺ titers were reduced 3- and 10-fold following treatment with 200 or 400 μ M 5-FU, respectively (Figure 3C). In contrast, SARS-ExoN⁻ titers were reduced ~300-fold by 200 μ M 5-FU (Figure 3C), similar to MHV-ExoN⁻ viruses. At 400 μ M 5-FU, SARS-ExoN⁻ virus was inhibited 2,000-fold during a single replication cycle, representing a ~160-fold increase in 5-FU sensitivity compared to SARS-ExoN⁺ viruses. Thus, our data indicate that increased sensitivity of CoVs to RNA mutagens in the absence of ExoN activity is conserved across diverse members of the CoV family. Of interest, our studies with SARS-ExoN⁺ also indicate that ExoN-mediated protection from nucleotide misincorporation can be overcome at higher concentrations of mutagen.

5-FU drives increased mutagenesis in both SARS-ExoN⁺ and ExoN⁻ viruses

Studies with the RNA viruses lymphocytic choriomeningitis virus (LCMV), foot-and-mouth disease virus (FMDV) and vesicular stomatitis virus (VSV) have demonstrated that 5-FU is incorporated as 5-fluorouridine monophosphate (FUMP) into replicating viral RNA, thus increasing genomic mutations [60–62]. To determine whether 5-FU was causing increased mutagenesis in SARS-CoV populations, we performed full-genome NGS analysis of both virus populations replicating in the presence or absence of 5-FU. To analyze the entire spectrum of mutations arising during replication, we extracted total intracellular RNA from Vero cells infected with either SARS-ExoN⁺ or ExoN⁻ viruses following treatment with either 0 μ M or 400 μ M 5-FU. We then generated 12 overlapping cDNA amplicons of approximately 3 kb in length for each sample. For each of the four samples, 1.4×10^8 to 4.5×10^8 bases were sequenced, corresponding to an average coverage depth of between 4,600 and 15,000 at each nucleotide position. We compared the statistically significant minority variants, defined as having a p-value of ≤ 0.05 following a multiple-testing correction (Benjamini-Hochberg), between the untreated and 5-FU-treated SARS-ExoN⁺ and ExoN⁻ populations. Following treatment with 400 μ M 5-FU (Figure 3D), there was an increase in mutations within the SARS-ExoN⁺ population from 11 to 259 (24-fold). In contrast, for SARS-ExoN⁻ there were 3648 mutations present within the 5-FU-treated SARS-ExoN⁻ population compared to the 99 mutations in the untreated population (40-fold increase). Most remarkably, this represented a 16-fold increase in the number of statistically significant minority variants between 5-FU treated ExoN⁺ and ExoN⁻ SARS-CoV. Thus, these data support our hypothesis that 5-FU was increasing genomic mutations through incorporation of FUMP into viral genomes in the absence of ExoN activity.




Figure 3. SARS-ExoN⁻ viruses have increased sensitivity to 5-FU. (A) Vero cells in 96-well plates were incubated with DMEM alone, or DMEM containing 20% ethanol (EtOH), 4% DMSO, or the indicated concentration of RBV or 5-FU for 24 h. Cell viability was determined using CellTiter-Glo (Promega) according to manufacturer's instructions. All values were normalized to the untreated (DMEM) control. Mean values \pm S.E.M. are shown, $n=3$. The change in SARS-ExoN⁺ (filled blue circles) and SARS-ExoN⁻ (empty green circles) titers following treatment with RBV (B) or 5-FU (C) during single-cycle replication. Vero cells were infected with either virus at an MOI of 0.1 PFU/cell, and virus supernatant was harvest 24 h post-infection following replication in the presence or absence of RBV or 5-FU. Virus titer was determined by plaque assay on Vero cells. Mean values \pm S.E.M. are shown, $n=2$ (RBV) and $n=4$ (5-FU). (D) Comparison of unique statistically significant ($P<0.05$) minority variants present between untreated and 5-FU treated samples for both SARS-ExoN⁺ and ExoN⁻ populations. SARS-ExoN⁺ viruses are shown in blue, and SARS-ExoN⁻ viruses are shown in green. For panels A–C statistical significance was determined using an unpaired, two-tailed Student's t test (* $P<0.05$, ** $P<0.01$, *** $P<0.0001$). doi:10.1371/journal.ppat.1003565.g003

5-FU-associated A-to-G and U-to-C transitions are highly represented and distributed across the genome

Incorporation of FUMP instead of uracil into replicating RNA allows FUMP to base pair with both guanosine and adenine [61,63]. This decreased specificity in base pairing has been shown in studies with LCMV and primarily results in A-to-G (A:G) and U-to-C (U:C) transitions [29,61,63]. To determine if FUMP was being incorporated at higher levels in the absence of ExoN-mediated proofreading, we analyzed the numbers and types of transitions and transversions occurring in each virus population (Figure 4). Transitions are indicated in grey boxes and transversions in white boxes, with the number for each shown. Transversions comprised the majority of variants for both untreated ExoN⁻ and ExoN⁺ viruses. Treatment with 5-FU caused the number of U:C and A:G transitions to increase in both ExoN⁺ and ExoN⁻ populations, from 2 to 197 for SARS-ExoN⁺ and from 16 to 3304 for SARS-ExoN⁻ (Figures 4A and B). This increase and bias toward U:C and A:G transitions is consistent with FUMP being incorporated into both minus- and plus-strand

RNA [63] during both ExoN⁺ and ExoN⁻ replication; however the absolute numbers were dramatically increased (16-fold) during ExoN⁻ replication compared to ExoN⁺. In untreated cells, A:G and U:C transitions accounted for less than 25% of the total minority variants within each population (Figure 4C). Following 5-FU treatment, A:G and U:C transitions accounted for 70–95% of the total minority variants within each population.

To further examine the genomic distribution of these two transitions, we plotted the total number of A:G and U:C transitions occurring at a frequency of between 0.1% and 1% (Figure 5). Approximately 75% and 90% of the total minority variants occurring at a frequency between 0.1 and 1% following 5-FU treatment were due to A:G or U:C transitions (Figure 5), for the SARS-ExoN⁺ and ExoN⁻ populations, respectively. In both populations, these mutations were distributed across the entire genome following treatment with 400 μ M 5-FU. Thus our data provide direct evidence indicating that 5-FU drives increased genomic mutations within SARS-CoV in the absence of ExoN proofreading activity.




Figure 4. Incorporation of FUMP results in increased U:C and A:G transitions. All possible base changes are shown for SARS-ExoN+ and SARS-ExoN- viruses in panels (A) and (B), respectively. Transitions (A↔G and U↔C) are shaded in grey, and 5-FU specific transitions (U:C and A:G) are marked with an asterisk. Transversions (A↔T, A↔C, C↔G, G↔T) are shown in white boxes. All values represent the number of unique statistically significant minority variants following 5-FU treatment. (C) The percent of all unique statistically significant minority variants represented by transversions (filled dark grey bars), C:U and G:A transitions (filled light grey bars), and the 5-FU specific transitions A:G (hatched bars) and U:C (checkered bars) are shown following 0 or 400 μM 5-FU treatment. SARS-ExoN+ viruses are shown in blue, and SARS-ExoN- viruses are shown in green. doi:10.1371/journal.ppat.1003565.g004

Discussion

Viral sensitivity to RNA mutagens is determined by several factors including polymerase selectivity [39,40,64–67], mutational robustness [68], and the acquisition of mutations that increase or decrease replication fidelity. Increased and decreased fidelity mutants have been described for picornaviruses and arboviruses [35,48,50,69], all of which have occurred in the viral RdRp. The

CoV nsp14-ExoN is the first identified RNA virus protein distinct from the RdRp that affects replication fidelity [19–21,70]. While the G641D mutation within the chikungunya (CHIKV) nonstructural protein 2 (nsP2) has been implicated in CHIKV resistance to RBV, a direct role for this protein in fidelity regulation has not been described [48]. A Sindbis virus variant containing mutations within nsP1, a viral guanylyl- and methyltransferase [71], has been shown to be resistant to both RBV and MPA [72]. However, this phenotype is related to viral RNA capping and not replication fidelity [72]. In this report, we identify CoV ExoN activity as a critical determinant of viral sensitivity to RNA mutagens. Using two phylogenetically distant β-CoVs we demonstrate that this phenotype is well conserved across CoVs. Clearly, there is a profound increase both in overall mutations and in specific 5-FU-associated mutations within the ExoN- population as compared to the ExoN+ wild-type population. Furthermore, the vast majority of statistically significant mutations were distributed genome-wide at frequencies between 0.2 and 1%, providing strong evidence supporting ExoN-mediated proofreading during CoV replication. Of interest, our experiments also revealed that ExoN-mediated prevention and/or removal of misincorporated nucleotides is not absolute, especially in the setting of higher concentrations of mutagen. ExoN+ SARS-CoV populations demonstrated 24-fold more mutations following 5-FU treatment, suggesting that ExoN proofreading can be overwhelmed by higher concentrations of mutagens and likely by other nucleoside or base analogs. This raises the further possibility that ExoN may be less efficient at recognizing or removing some types of nucleoside or base analogs than others, and that such approaches to virus inhibition might be viable, particularly in combination with inhibitors that target ExoN activity.

Ribavirin activity against CoVs is not primarily due to mutagenesis

The antiviral nucleoside analog RBV is currently used to treat hepatitis C virus (HCV; [73–75]), Lassa virus [76] and respiratory syncytial virus (RSV) infections [77,78]. The potential clinical use of RBV for CoV infections is complicated by the multiple mechanisms of action that have been reported [38], and by the potential for disease exacerbation, as reported during the SARS-CoV epidemic [25–28]. Our data suggest that RBV primarily inhibits MHV-ExoN- virus replication through decreasing viral RNA synthesis and inhibition of IMPDH (Figure 1). Inhibition of IMPDH by RMP has been shown to decrease intracellular GTP pools [51], thus altering the balance of nucleoside triphosphates (NTPs) within the cell. Decreased GTP levels could result in forced misincorporations due to NTP imbalances in the absence of ExoN activity [72]. However, the moderate 6- to 9-fold decreases in relative specific infectivity observed for MHV-ExoN- following RBV treatment (Table 1) suggests that mutagenesis is not the primary mechanism by which RBV is exerting an antiviral effect. An additional possibility is that the antiviral activity of RBV against ExoN- viruses is unrelated to the putative proofreading function of this enzyme. Both biochemical and cell culture studies have demonstrated that loss of ExoN activity leads to impaired RNA synthesis [15,19,20]. Furthermore, in addition to ExoN activity, nsp14 contains N7-methyltransferase (N7-MTase) activity, a critical step in RNA capping [79,80]. A recent report has demonstrated that the ExoN and N7-MTase domains are structurally inseparable, and that residues within the ExoN domain are important for N7-MTase activity [81]. Thus, the increased sensitivity of MHV-ExoN- to RBV could result from the impairment of undefined functions of ExoN during CoV replication, particularly during RNA synthesis. The parallel use of




Figure 5. 5-FU-mediated U:C and A:G transitions are distributed across the CoV genome at low frequency. (A) and (B) The genomic distribution of low frequency statistically significant U:C and A:G variants within the SARS-ExoN+ population following treatment with 0 or 400 μ M 5-FU. (C) and (D) Same as in A and B except for the SARS-ExoN- population. For all panels, SARS-ExoN+ viruses are shown in blue, and SARS-ExoN- viruses are shown in green. U:C transitions are denoted by a diamond, whereas A:G transitions are plotted as circles. doi:10.1371/journal.ppat.1003565.g005

ExoN+ and ExoN- viruses with RBV may allow us to define how RBV is exerting an antiviral effect against CoVs and the potentially novel mechanisms by which ExoN may act to counter that inhibition.

ExoN proofreading during CoV replication

Since the identification of nsp14-ExoN activity [15] and studies demonstrating the requirement for ExoN in high-fidelity replication [19–21], mounting evidence points to a role for nsp14-ExoN in proofreading activity during RNA virus replication [22]. Here we used NGS to determine the number of mutations present in SARS-ExoN+ and ExoN- populations. The characteristic 5-FU-mediated transitions U:C and A:G comprised 90% of the total statistically significant minority variants within SARS-ExoN- population, and were present at levels 15- and 20-fold higher than those same transitions within the ExoN+ population (Figure 4). Overall, our data represent the first direct test of ExoN proofreading during SARS-CoV replication in the absence of

ExoN. Furthermore, the sequencing depth attained using NGS shows that ExoN inactivation likely skews the spectrum of spontaneous mutations present within the untreated population (Figure 4). Such overrepresentation of specific mutations in the context of ExoN inactivation is similar to studies of *S. cerevisiae* DNA polymerases ϵ and δ containing mutations within their respective 3'-to-5' DEDD exonucleases [82–86]. This altered distribution due to ExoN inactivation could have profound implications for CoV adaptation and evolution.

Nsp14-ExoN as a target for combination CoV inhibitors

Lethal mutagenesis occurs through the accumulation of mutations within the viral genome during replication, and ultimately results in virus extinction (reviewed in [56,87]). While lethal mutagenesis has been studied extensively [87], our work is the first to identify an RNA virus protein distinct from the RdRp that directly regulates the sensitivity of RNA viruses to genomic mutations resulting from mutagen incorporation. Currently, RBV

is the only FDA-approved antiviral with demonstrated mutagenic activity. The first demonstration of RBV acting as a mutagen was performed using poliovirus [23,24] almost 30 years after the antiviral activity of RBV was described [88]. The nucleoside analog T-705 (Favipiravir; [89]) is currently in clinical development, and has been shown recently to drive lethal mutagenesis of influenza virus [90]. We have shown that ExoN⁺ viruses replicate well in the presence of RBV or 5-FU. However, we also have shown that ExoN[−] mutants of SARS-CoV and MHV have 15- to 20-fold decreased fidelity [19,20], are attenuated, are subject to rapid loss of replication and clearance *in vivo* [21], and are highly susceptible to low concentrations of RNA mutagens. An exciting possibility is that this conserved CoV proofreading enzyme could be targeted for inhibition, thus leading to the development of broadly useful CoV therapeutics. While ExoN inhibitors alone might be efficacious, combining an inhibitor of CoV fidelity with an RNA mutagen would magnify the intrinsic fidelity defect of ExoN inhibition and drive high-level mutagenesis. A potential advantage of such an approach would be to rapidly drive the virus to extinction, while limiting or blocking the capacity of the virus to overcome inhibition by reversion. ExoN[−] mutants of both MHV and SARS-CoV have shown no reversion over multiple passages in culture or during persistent infections *in vivo* [19–21]. Furthermore, we did not observe any primary reversions within the ExoN DEDD motif following 5-FU treatment. While mutations within the CoV RdRp could emerge during acute treatment, mutations within other RNA virus RdRps have demonstrated that the maximum tolerance for increased or

decreased fidelity without loss of virus viability is between ~3- to 6-fold [35,48,69,91]. In addition, our data demonstrate that ExoN[−] viruses are profoundly sensitive to inhibition by lower concentrations of mutagen, providing a possible improved therapeutic index and margin of safety for use.

In summary, this study provides the most direct evidence to date that CoV ExoN provides a proofreading function during virus replication, and identifies ExoN as the critical determinant of CoV sensitivity to RNA mutagens. Because CoV replication fidelity is likely determined by the concerted effort of multiple virus proteins [19,20,22], our data suggest the exciting possibility that significant attenuation of CoV fitness and pathogenesis could be achieved by targeting the conserved process of CoV replication fidelity. Ultimately, uncovering the mechanism of fidelity regulation and methodologies to disrupt this critical process will be vital to responding to both endemic and future emerging CoVs such as SARS-CoV and MERS-CoV.

Acknowledgments

We thank Ofer Isakov and Noam Shomron at Tel Aviv University for their help in NGS bioinformatics analysis and Michelle Becker at Vanderbilt University Medical Center for critical reading of the manuscript.

Author Contributions

Conceived and designed the experiments: ECS MV MRD. Performed the experiments: ECS. Analyzed the data: ECS HB. Wrote the paper: ECS MV MRD.

References

- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med* 367: 1814–1820.
- Perlman S, Netland J (2009) Coronaviruses post-SARS: update on replication and pathogenesis. *Nat Rev Microbiol* 7: 439–450.
- Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med* 348: 1967–1976.
- Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, et al. (2003) A novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med* 348: 1953–1966.
- Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, et al. (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet* 361: 1319–1325.
- ProMED-mail. (2012) Novel coronavirus - Saudi Arabia: human isolate. 20 Sep: 20120920.1302733. <<http://www.promedmail.org>> Accessed 26 Apr 2013.
- Vijaykrishna D, Smith GJ, Zhang JX, Peiris JS, Chen H, et al. (2007) Evolutionary insights into the ecology of coronaviruses. *J Virol* 81: 4012–4020.
- Pfefferle S, Oppong S, Drexler JF, Gloza-Rausch F, Ipsen A, et al. (2009) Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana. *Emerg Infect Dis* 15: 1377–1384.
- Gloza-Rausch F, Ipsen A, Seebens A, Gottsche M, Panning M, et al. (2008) Detection and prevalence patterns of group I coronaviruses in bats, northern Germany. *Emerg Infect Dis* 14: 626–631.
- Huynh J, Li S, Yount B, Smith A, Sturges L, et al. (2012) Evidence supporting a zoonotic origin of human coronavirus strain NL63. *J Virol* 86: 12816–12825.
- van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, et al. (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. *MBio* 3: e00473–12.
- Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, et al. (2012) Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. *Euro Surveill* 17: 20290.
- ProMED-mail. (2013) MERS-CoV - Eastern Mediterranean (31): Jordan, retro. case ID, WHO, RFL 17 June: 20130617.1777989 <<http://www.promedmail.org>> Accessed 18 June 2013.
- Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, et al. (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. *Nature* 495: 251–254.
- Minskaia E, Hertz T, Gorbalenya AE, Campanacci V, Cambillau C, et al. (2006) Discovery of an RNA virus 3'→5' exoribonuclease that is critically involved in coronavirus RNA synthesis. *Proc Natl Acad Sci U S A* 103: 5108–5113.
- Gorbalenya AE, Enjuanes L, Ziebuhr J, Snijder EJ (2006) Nidovirales: evolving the largest RNA virus genome. *Virus Res* 117: 17–37.
- Smith EC, Denison MR (2012) Implications of altered replication fidelity on the evolution and pathogenesis of coronaviruses. *Curr Opin Virol* 2: 519–524.
- Zuo Y, Deutscher MP (2001) Exoribonuclease superfamilies: structural analysis and phylogenetic distribution. *Nucleic Acids Res* 29: 1017–1026.
- Eckerle LD, Becker MM, Halpin RA, Li K, Venter E, et al. (2010) Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. *PLoS Pathog* 6: e1000896.
- Eckerle LD, Lu X, Sperry SM, Choi L, Denison MR (2007) High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. *J Virol* 81: 12135–12144.
- Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, et al. (2012) A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. *Nat Med* 18: 1820–1826.
- Bouvet M, Imbert I, Subissi L, Gluais L, Canard B, et al. (2012) RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex. *Proc Natl Acad Sci U S A* 109: 9372–9377.
- Crotty S, Cameron CE, Andino R (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. *Proc Natl Acad Sci U S A* 98: 6895–6900.
- Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, et al. (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. *Nat Med* 6: 1375–1379.
- Chiou HE, Liu CL, Buttrey MJ, Kuo HP, Liu HW, et al. (2005) Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. *Chest* 128: 263–272.
- Muller MP, Dresser L, Raboud J, McGeer A, Rea E, et al. (2007) Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. *Pharmacotherapy* 27: 494–503.
- Barnard DL, Day CW, Bailey K, Heimer M, Montgomery R, et al. (2006) Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. *Antiviral Res* 71: 53–63.
- Stockman LJ, Bellamy R, Garner P (2006) SARS: systematic review of treatment effects. *PLoS Med* 3: e343.
- Grande-Perez A, Sierra S, Castro MG, Domingo E, Lowenstein PR (2002) Molecular indeterminism in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. *Proc Natl Acad Sci U S A* 99: 12938–12943.
- Yount B, Denison MR, Weiss SR, Baric RS (2002) Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. *J Virol* 76: 11065–11078.
- Yount B, Curtis KM, Fritz EA, Hensley LE, Jahrling PB, et al. (2003) Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. *Proc Natl Acad Sci U S A* 100: 12995–13000.

32. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the $2(-\Delta\Delta C_T)$ Method. *Methods* 25: 402–408.
33. Donaldson EF, Sims AC, Graham RL, Denison MR, Baric RS (2007) Murine hepatitis virus replicase protein nsp10 is a critical regulator of viral RNA synthesis. *J Virol* 81: 6356–6368.
34. Donaldson EF, Sims AC, Deming DJ, Baric RS (2006) Mutational analysis of MHV-A59 replicase protein-nsp10. *Adv Exp Med Biol* 581: 61–66.
35. Gnadig NF, Beaucourt S, Campagnola G, Borderia AV, Sanz-Ramos M, et al. (2012) Cocksackievirus B3 mutator strains are attenuated in vivo. *Proc Natl Acad Sci U S A* 109: E2294–2303.
36. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25: 1754–1760.
37. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25: 2078–2079.
38. Crotty S, Cameron C, Andino R (2002) Ribavirin's antiviral mechanism of action: lethal mutagenesis? *J Mol Med (Berl)* 80: 86–95.
39. Agudo R, Ferrer-Orta C, Arias A, de la Higuera I, Perales C, et al. (2010) A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. *PLoS Pathog* 6: e1001072.
40. Arias A, Arnold JJ, Sierra M, Smidansky ED, Domingo E, et al. (2008) Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. *J Virol* 82: 12346–12355.
41. Maag D, Castro C, Hong Z, Cameron CE (2001) Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. *J Biol Chem* 276: 46094–46098.
42. Sierra M, Airaksinen A, Gonzalez-Lopez C, Agudo R, Arias A, et al. (2007) Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. *J Virol* 81: 2012–2024.
43. Kamiya K, Huang P, Plunkett W (1996) Inhibition of the 3'→5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA. *J Biol Chem* 271: 19428–19435.
44. Lim SE, Copeland WC (2001) Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. *J Biol Chem* 276: 23616–23623.
45. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, et al. (2001) Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. *J Biol Chem* 276: 40847–40857.
46. Lee H, Hanes J, Johnson KA (2003) Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. *Biochemistry* 42: 14711–14719.
47. Arnold JJ, Sharma SD, Feng JY, Ray AS, Smidansky ED, et al. (2012) Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. *PLoS Pathog* 8: e1003030.
48. Coffey LL, Beeharry Y, Borderia AV, Blanc H, Vignuzzi M (2011) Arbovirus high fidelity variant loses fitness in mosquitoes and mice. *Proc Natl Acad Sci U S A* 108: 16038–16043.
49. Vignuzzi M, Wendt E, Andino R (2008) Engineering attenuated virus vaccines by controlling replication fidelity. *Nat Med* 14: 154–161.
50. Pfeiffer JK, Kirkegaard K (2003) A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. *Proc Natl Acad Sci U S A* 100: 7289–7294.
51. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, et al. (1973) Mechanism of action of 1- β -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. *Proc Natl Acad Sci U S A* 70: 1174–1178.
52. Carter SB, Franklin TJ, Jones DF, Leonard BJ, Mills SD, et al. (1969) Mycophenolic acid: an anti-cancer compound with unusual properties. *Nature* 223: 848–850.
53. Carr SF, Papp E, Wu JC, Natsumeda Y (1993) Characterization of human type I and type II IMP dehydrogenases. *J Biol Chem* 268: 27286–27290.
54. Franklin TJ, Cook JM (1969) The inhibition of nucleic acid synthesis by mycophenolic acid. *Biochem J* 113: 515–524.
55. Takhampunya R, Ubol S, Houg HS, Cameron CE, Padmanabhan R (2006) Inhibition of dengue virus replication by mycophenolic acid and ribavirin. *J Gen Virol* 87: 1947–1952.
56. Domingo E, Sheldon J, Perales C (2012) Viral quasispecies evolution. *Microbiol Mol Biol Rev* 76: 159–216.
57. Ibarra KD, Pfeiffer JK (2009) Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance. *J Virol* 83: 4538–4547.
58. Shah NR, Sunderland A, Grdzelskivili VZ (2010) Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. *PLoS ONE* 5: e11265.
59. Cinalt J, Morgenstern B, Bauer G, Chandra P, Rabenau H, et al. (2003) Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. *Lancet* 361: 2045–2046.
60. Moreno H, Tejero H, de la Torre JC, Domingo E, Martin V (2012) Mutagenesis-mediated virus extinction: virus-dependent effect of viral load on sensitivity to lethal defection. *PLoS ONE* 7: e32550.
61. Agudo R, Arias A, Pariente N, Perales C, Escarmis C, et al. (2008) Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. *J Mol Biol* 382: 652–666.
62. de la Torre JC (2005) Arenavirus extinction through lethal mutagenesis. *Virus Res* 107: 207–214.
63. Agudo R, Arias A, Domingo E (2009) 5-fluorouracil in lethal mutagenesis of foot-and-mouth disease virus. *Future Med Chem* 1: 529–539.
64. Arnold JJ, Vignuzzi M, Stone JK, Andino R, Cameron CE (2005) Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. *J Biol Chem* 280: 25706–25716.
65. Gong P, Peersen OB (2010) Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase. *Proc Natl Acad Sci U S A* 107: 22505–22510.
66. Thompson AA, Albertini RA, Peersen OB (2007) Stabilization of poliovirus polymerase by NTP binding and fingers-thumb interactions. *J Mol Biol* 366: 1459–1474.
67. Prindle MJ, Schmitt MW, Parmeggiani F, Loeb LA (2013) A substitution in the fingers domain of DNA polymerase delta reduces fidelity by altering nucleotide discrimination in the catalytic site. *J Biol Chem* 288: 5572–5580.
68. Graci JD, Gnadig NF, Galarra JA, Castro C, Vignuzzi M, et al. (2012) Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis. *J Virol* 86: 2869–2873.
69. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R (2006) Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. *Nature* 439: 344–348.
70. Denison MR, Graham RL, Donaldson EF, Eckerle LD, Baric RS (2011) Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. *RNA Biol* 8: 270–279.
71. Mi S, Durbin R, Huang HV, Rice CM, Stollar V (1989) Association of the Sindbis virus RNA methyltransferase activity with the nonstructural protein nsp1. *Virology* 170: 385–391.
72. Scheidel LM, Stollar V (1991) Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsp1. *Virology* 181: 490–499.
73. Mams MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, et al. (2007) The way forward in HCV treatment—finding the right path. *Nat Rev Drug Discov* 6: 991–1000.
74. Cummings KJ, Lee SM, West ES, Cid-Ruza JA, Fein SG, et al. (2001) Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. *JAMA* 285: 193–199.
75. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, et al. (1998) Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. *N Engl J Med* 339: 1493–1499.
76. McCormick JB, King TJ, Webb PA, Scribner CL, Craven RB, et al. (1986) Lassa fever. Effective therapy with ribavirin. *N Engl J Med* 314: 20–26.
77. Hall CB, Walsh EE, Hruska JF, Betts RF, Hall WJ (1983) Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. *JAMA* 249: 2666–2670.
78. Wyde PR (1998) Respiratory syncytial virus (RSV) disease and prospects for its control. *Antiviral Res* 39: 63–79.
79. Bouvet M, Debarnot C, Imbert I, Selisko B, Snijder EJ, et al. (2010) In vitro reconstitution of SARS-coronavirus mRNA cap methylation. *PLoS Pathog* 6: e1000863.
80. Chen Y, Cai H, Pan J, Xiang N, Tien P, et al. (2009) Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase. *Proc Natl Acad Sci U S A* 106: 3484–3489.
81. Chen Y, Tao J, Sun Y, Wu A, Su C, et al. (2013) Structure-function Analysis of SARS Coronavirus RNA Cap Guanine-N7 Methyltransferase. *J Virol* [epub ahead of print] doi: 10.1128/JVI.00061-13
82. Fortune JM, Pavlov YI, Welch CM, Johansson E, Burgers PM, et al. (2005) *Saccharomyces cerevisiae* DNA polymerase delta: high fidelity for base substitutions but lower fidelity for single- and multi-base deletions. *J Biol Chem* 280: 29980–29987.
83. Karthikeyan R, Vonnarx EJ, Straffon AF, Simon M, Faye G, et al. (2000) Evidence from mutational specificity studies that yeast DNA polymerases delta and epsilon replicate different DNA strands at an intracellular replication fork. *J Mol Biol* 299: 405–419.
84. Reha-Krantz IJ, Stocki S, Nonay RL, Dimayuga E, Goodrich LD, et al. (1991) DNA polymerization in the absence of exonucleolytic proofreading: in vivo and in vitro studies. *Proc Natl Acad Sci U S A* 88: 2472–2471.
85. Morrison A, Sugino A (1994) The 3'→5' exonucleases of both DNA polymerases delta and epsilon participate in correcting errors of DNA replication in *Saccharomyces cerevisiae*. *Mol Gen Genet* 242: 289–296.
86. Shcherbakova PV, Pavlov YI, Chilkova O, Rogozin IB, Johansson E, et al. (2003) Unique error signature of the four-subunit yeast DNA polymerase epsilon. *J Biol Chem* 278: 43770–43780.
87. Perales C, Martin V, Domingo E (2011) Lethal mutagenesis of viruses. *Curr Opin Virol* 1: 419–422.
88. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, et al. (1972) Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. *Science* 177: 705–706.
89. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, et al. (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. *Antimicrob Agents Chemother* 46: 977–981.
90. Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, et al. (2013) T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. *J Virol* 87: 3741–3751.
91. Pfeiffer JK, Kirkegaard K (2005) Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. *PLoS Pathog* 1: e11.